Register Login
Register to leave comments
  • News bot May 7, 2026, 10:23 p.m.

    🔍 EVNIN LUKE (Executive)

    Company: Werewolf Therapeutics, Inc. (HOWL)

    Report Date: 2026-05-05

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 100,581

    Detailed Transactions and Holdings:

    • Sold 6,860 shares of Common Stock at $0.69 per share (Direct)
      Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,672,470.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F4
    • Sold 14,635 shares of Common Stock at $0.66 per share (Direct)
      Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,657,835.00 | transaction_form_type: 4 | Footnotes: F1, F6, F7, F4
    • Sold 79,086 shares of Common Stock at $0.63 per share (Direct)
      Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,578,749.00 | transaction_form_type: 4 | Footnotes: F1, F9, F10, F4

    Footnotes:

    • F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
    • F2: The shares were sold as follows: 735 by MPM Asset Management LLC ("AM LLC"), 4,640 by MPM BioVentures 2014, L.P. ("BV 2014"), 310 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 160 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,015 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6616 to $0.7253 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
    • F5: The shares are held as follows: 179,188 by AM LLC, 1,131,359 by BV 2014, 75,458 by BV 2014(B), 38,939 by AM BV2014 and 247,526 by MPM OIF.
    • F6: The shares were sold as follows: 1,568 by AM LLC, 9,900 by BV 2014, 660 by BV 2014(B), 341 by AM BV2014 and 2,166 by MPM OIF.
    • F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.7054 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F8: The shares are held as follows: 177,620 by AM LLC, 1,121,459 by BV 2014, 74,798 by BV 2014(B), 38,598 by AM BV2014 and 245,360 by MPM OIF.
    • F9: The shares were sold as follows: 8,473 by AM LLC, 53,499 by BV 2014, 3,568 by BV 2014(B), 1,841 by AM BV2014 and 11,705 by MPM OIF.
    • F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.667 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F11: The shares are held as follows: 169,147 by AM LLC, 1,067,960 by BV 2014, 71,230 by BV 2014(B), 36,757 by AM BV2014 and 233,655 by MPM OIF.

Search

News categories